Navigation Links
3SBio Inc. to Present at the UBS Greater China Conference 2012

SHENYANG, China, Jan. 9, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced Mr. Bo Tan, 3SBio's chief financial officer will attend the UBS Greater China Conference 2012 in Shanghai on January 11, 2012. A copy of Mr. Tan's presentation will be archived at under the investor relations section.  

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and MP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see for more information.

Investor Contacts

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991

Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. 3SBio Inc. Announces Results of 2011 Annual General Meeting
2. 3SBio Inc. Announces Unaudited First Quarter 2011 Results
3. 3SBio Inc. Schedules Unaudited First Quarter 2011 Results
4. 3SBio Inc. Schedules Unaudited Fourth Quarter and Fiscal Year 2010 Results
5. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
6. 3SBio Inc. Announces Unaudited Third Quarter Results
7. 3SBio Inc. Announces Unaudited Second Quarter Results
8. 3SBio Inc. Schedules Second Quarter 2010 Unaudited Financial Results
9. 3SBio Inc. Announces Filing of Form 20-F With SEC
10. 3SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010
11. 3SBio Announces Changes to its Board of Directors
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):